Latest Health News

Racura Oncology has hit key clinical milestones in its RC220 development, including first patient dosing in a lung cancer trial and dose escalation in a cardioprotection study, supported by a strong $34.3 million cash position.

Dotz Nano has appointed Nati Harpaz as CEO, introduced Dotz Energy to extend its decarbonisation efforts, and secured $3.3 million in fresh funding to accelerate commercialisation and production scale-up.

LTR Pharma’s SPONTAN shows rapid absorption in Phase II interim data while securing key US commercial deals for ROXUS, setting the stage for a US market entry later this year.

Elixinol Wellness posted a record quarterly revenue of $4.3 million in Q2 FY26, driven by The Healthy Chef's expansion and a 45% gross margin. Cost cuts helped deliver positive underlying operating cash flow for the third straight quarter despite some one-off expenses.

ImpediMed reported a 3% revenue increase to $3.6 million in Q4 FY26, bolstered by a $15.3 million capital raise and strategic leadership hires as it pushes growth in cancer survivorship, heart health, and weight management.

Argent BioPharma has eliminated US$5.5 million in secured debt through a global licensing agreement for its CannEpil® epilepsy therapy, while completing a key acquisition and advancing clinical trials in veterinary therapeutics.

RLF AgTech posted a seasonally strong June quarter with $7.1 million in cash receipts, driven by record pre-season payments in China and tight cost control that brought operating cash flow close to breakeven.

Nex Metals Explorations reports metallurgical test results confirming ~1 g/t gold grades at its Kookynie Tailings Project, alongside the unexpected identification of scheelite, a tungsten mineral, as a potential byproduct.

Proteomics International Laboratories has streamlined operations, secured a key US patent for its endometriosis test, and inked a three-year exclusive distribution deal with Healius for its Promarker diagnostics in Australia.

Echo IQ has locked in a strategic $20 million investment and US partnership with Pro Medicus, alongside a $110 million capital raise, positioning the company for accelerated commercial expansion of its AI-driven cardiovascular diagnostics in the US.

Biome Australia (ASX: BIO) edged close to breakeven in FY26, driven by $1.8 million in international sales across four markets and a 68% gross margin. The company is set to launch onshore manufacturing and a digital health platform to accelerate growth.

Australian Foundation Investment Company (ASX:AFI) posted a 3% increase in net profit for FY26, holding dividends steady with a special payout amid portfolio underperformance against the ASX 200.